Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Pfe crawled date : 2021 - 05 - 04 save search
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
Published: 2021-05-04 (Crawled : 13:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.43%
H: 0.43%
C: -0.13%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.19%
H: 0.29%
C: -0.27%
new drug fda drug hiv submission application
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.07%
H: 1.11%
C: -0.67%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.43%
H: 0.43%
C: -0.13%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 1.72%
H: 0.31%
C: -16.76%
results report
Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Published: 2021-05-04 (Crawled : 07:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.43%
H: 0.43%
C: -0.13%
europe prostate cancer cancer hormone approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.